SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...

Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to diagnose prostate cancer and a presentation by Dr. Gerhardt Attard discussing molecular tests at diagnosis for ...